ChemoSNiP™:
A Liquid Biopsy Pharmacogenomic
Test

Genetic Test for
Chemotherapy Response.

ChemoSNiP™

Every patient's genetic code is different.

Those differences influence how your body handles certain chemotherapy drugs and other therapeutic substances. The same drug, at the same dose, doesn't behave the same way in every body.

Some people process it as expected.

Others experience side effects that seem disproportionate to the dose, or a treatment that doesn’t seem to work the way it should — and the reason often lies in how your body processes the drug, not just the treatment itself.

ChemoSNiP™ is a liquid biopsy test that looks at more than 100 genetic variations involved in how your body breaks down, transports, and clears certain chemotherapy drugs and natural substances. Instead of starting with a standard dose and adjusting based on how you respond, your medical team has this information before treatment begins — one more thing they can factor in when planning your care.

What Exactly Is ChemoSNiP™

As a liquid biopsy test, ChemoSNiP™ functions as a pharmacogenomic test — everyone has these same 100 spots, but the exact version you got is a little different from person to person, like slightly different settings on the same 100 dials.
That’s why the same drug, at the same dose, can work differently for two people — it’s not about who’s “more sick,” it’s about which version of those 100 dials they were born with.
1
ChemoSNiP™ Looks at Your Genes

You already know genes decide things like your eye color or height. They also decide something less visible: how your body handles drugs.

2
Over 100 Genetic Variations

ChemoSNiP™ checks over 100 small spots in your DNA that affect how fast your body breaks a drug down, moves it around, and gets rid of it.

What the Test Looks At

ChemoSNiP™ examines genetic variations across four biological pathways — drug metabolism, drug transport, detoxification, and DNA repair — giving your medical team a broader picture of how your specific body may handle certain chemotherapy drugs and natural therapeutic substances.

What This Means for Your Treatment
Instead of starting with a standard dose and adjusting based on how you respond, your medical team has this information before treatment begins — one more input alongside everything else they already know about your case.
In practice, that could mean a different dose, a different drug, or just watching you more closely once treatment starts. Your medical team still makes every decision. This just means they’re not deciding blind.

Before the Key Is Chosen

As a liquid biopsy pharmacogenomic test, ChemoSNiP works like checking the lock before choosing the key: the drug is the key, your genes are the lock, and no two people’s locks are cut exactly the same way.
A drug that fits smoothly for one person may jam, or barely turn, for another. That’s not about the drug being wrong. It’s about the fit.

When the Key Jams

And when a key jams instead of turning smoothly, you don't usually get a clean click of rejection — you get a side effect, or a drug that clears from your system faster than expected, without warning.

Choosing a Dose Blind

Without that advance picture, your medical team chooses a dose based on what generally works for most people — and finds out whether it worked for you only by watching what happens after you've already started.


Seeing the Lock First

In practice, ChemoSNiP means your medical team can see the shape of the lock before choosing the key — a different dose, drug, or closer watching once treatment starts. They still choose. This just means they're not choosing blind.

Preparing to Start Treatment

Your genetic profile gives your medical team information about how your biology may interact with certain treatments before therapy starts.

Significant Side Effects or Unexpected Responses

Genetic information may provide additional context for understanding unexpected treatment responses.

Combining Treatment Approaches

Genetic information may provide context when conventional treatments are used alongside natural therapeutic substances.

A More Personalised Starting Point

Specific genetic information gives your medical team a starting point for a more precision-based, integrative approach to care.

The Genes Behind the Picture

ChemoSNiP examines genetic variations across key biological pathways to build a picture of how your body processes certain chemotherapy drugs — and, where relevant, natural substances too.

Drug Metabolism

Drug Metabolism

CYP450 family, GST, NAT, UGT

How your body activates and breaks down certain chemotherapy drugs.

DNA Repair

ERCC1, XRCC1

How your cells repair DNA damage after chemotherapy exposure.

Drug Transport & Resistance

MDR1, MRP, SLCO1B1

How certain drugs move into, through, and out of your cells.

Folate Pathways

MTHFR, TYMS, DHFR

How your body processes certain chemotherapy agents, including methotrexate.

Inflammatory Response

TNF, IL-6, SOD2, GPX1

How your body manages inflammation and oxidative stress during treatment.

It also examines genetic relevance to a range of natural substances, including curcumin, quercetin, resveratrol, genistein, green tea catechins, artemisinin, boswellia, vitamin D3, melatonin, sulforaphane, and indole-3-carbinol.
Every result is different, because every patient’s genetic profile is different. What a report actually shows depends entirely on what’s found in your own genes.

How ChemoSNiP™
Fits Into Your Treatment Plan

Cancer treatment planning is rarely based on a single test. Your medical team considers many different pieces of information — your diagnosis, medical history, pathology, imaging, and other clinical findings.

ChemoSNiP™ contributes another piece of that picture: information about the inherited genetic variations described earlier, and how they relate to certain chemotherapy drugs. These findings are interpreted alongside everything else your medical team already knows, not on their own.

For Some Patients

A result can confirm that the planned treatment fits well with their genetic profile — one less unknown going into treatment.


For Others

A result can surface something specific worth discussing with their medical team before treatment begins — not a red flag, just a detail worth factoring in.

Either way, this becomes part of the picture before treatment starts, not something discovered afterward.

Understanding Your Results with Oritov

A report is only the start.
Understanding what it means for you is what matters — and that’s where we come in.
1

We Help You Understand What the Results Show

Genetic findings can be unfamiliar and difficult to interpret on your own. We explain what the report shows, how certain genetic variations relate to the way your body processes and handles certain medicines, and the questions you may wish to discuss with your medical team.

2

Supporting Your Medical Team

ChemoSNiP™ provides additional genetic information that can become part of a broader discussion about your treatment. By helping both patients and healthcare professionals understand the report, we aim to make these conversations clearer and more informed.


Getting Started Is
Simpler Than You Think

1

Talk to Us

Tell us about your situation.
We will help you understand how this liquid biopsy pharmacogenomic test may be relevant to you and answer general questions about the process.

2

We Support Your Doctor Conversation

We provide educational resources about the testing pathway that you can share with your doctor — supporting a more informed discussion between you and your medical team.

3

We Handle the Coordination

Oritov coordinates the referral with a registered partner clinic in Singapore.
You focus on your health — we handle the rest.

4

A Simple Blood Draw

A blood sample is collected at a registered clinic by a qualified medical professional.
That is all that is needed from you.

5

Your Medical Team Receives the Report

Your laboratory report goes directly to your medical team.
Oritov provides educational support to help you and your doctor understand the genetic information — so your next care discussion with your medical team is better informed, with greater clarity.

CONTINUE EXPLORING

Continue Your Journey

CANFREE™ APPROACH
TO CANCER
Click here
Liquid Biopsy
Click here
Oncotrace™
Click here
Immune-Frame™
Click here
Onconomics Plus™
Click here
You Don't Have to Have All the Answers — Just the Question
You don’t need to be certain this liquid biopsy pharmacogenomic test is right for you. You just need to be willing to ask.
Some patients look back and wish they’d asked more questions before starting treatment.
Speaking with our team costs you nothing but a conversation — and it’s the kind of question you can only ask before treatment begins, not after.
Enquire Now
FREQUENTLY ASKED QUESTIONS
It does not predict treatment outcomes or tell you in advance whether a specific drug will be effective. As a liquid biopsy pharmacogenomic test, it looks at genetic variations that affect how your body processes certain drugs — see the sections above for how that works.

No. The initial conversation is there to help you and your medical team work out whether ChemoSNiP is relevant to your specific situation — including telling you if it isn’t. There’s no obligation to proceed after that conversation.

Your medical team does — always. Decisions about your treatment remain theirs and yours, made together.

Cost depends on your specific situation and testing pathway, and coverage varies. This is one of the things to raise in your first conversation with your medical team or with Oritov directly, so you have real numbers before deciding anything.

That depends on your specific timeline, and it’s a question worth raising directly with your medical team as early as possible. ChemoSNiP takes roughly 10–12 business days from sample collection to final results — the earlier this is discussed, the more options remain open.

DISCLAIMER